MRTX News and Press, Mirati Therapeutics Inc. From 12/02/20

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...

Cancer patients with K-Ras mutations comprise a large population with bleak prognosis and minimal treatment options. Recent breakthroughs in targeting only a small portion of K-Ras patients have made multibillion-dollar waves in the biotech sector. Despite failures from past compe...

Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO, Nov. 23, 2020 SAN DIEGO , Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announ...

Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology co...

Mirati Therapeutics (MRTX): Q3 GAAP EPS of -$1.96 beats by $0.07.Cash, cash equivalents, and short-term investments were $579.1M at September 30, 2020.Press Release For further details see: Mirati Therapeutics EPS beats by $0.07

Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights PR Newswire SAN DIEGO, Nov. 4, 2020 SAN DIEGO , Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology comp...

We are initiating coverage of Cardiff Oncology (CRDF) with a "VERY BULLISH" rating at a 30 PT. We project a worldwide peak sales north of US$1bn for mCRC indication only. CRDF shares have been steadily increasing since late Q2, with catalysts including robust clinical data of Onvanser...

Kala Pharmaceuticals on the go with upcoming PDUFA. Kezar announces Phase 2 KZR-616 trial update for polymyositis and dermatomyositis. Mirati Therapeutics announces positive clinical data for adagrasib. For further details see: Kala PDUFA, And Other News: The Good, Bad A...

Mirati Therapeutics (MRTX) has priced its public offering of ~4.3M common shares at $202.00/share, which consists of ~4M shares to be sold by Mirati and 375K by a selling stockholder.Gross proceeds should be ~$800M.Underwriters' over-allotment is an additional ~625K company's shares and 25K s...

Investors looking for biotech stocks to buy will notice lots of buzz around Amgen (NASDAQ: AMGN) and Mirati Therapeutics (NASDAQ: MRTX) lately. Both companies are developing similar new cancer treatments that could go on to generate billions in annual sales, and there are pl...